10th Annual World Patient Safety, Science & Technology Summit Begins
2.6.2023 09:15:00 EEST | Business Wire | Press release
Day one of the 10th Annual World Patient Safety, Science & Technology Summit presented by the Patient Safety Movement Foundation (PSMF) saw global leaders across the world of patient safety call for an increased urgency in addressing the issue of preventable harm within healthcare.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230601006140/en/
Joe Kiani, founder of the Patient Safety Movement Foundation, speaks at the 10th Annual World Patient Safety, Science & Technology Summit in Newport Beach, California. (Photo: Business Wire)
Celebrating the PSMF’s 10th anniversary, Dr. Michael Ramsay, chief executive officer of the PSMF, reflected on the role that the increasing availability of hospital data on medical errors could play in reducing harm. “I’m very optimistic that we’re really going to see a difference in healthcare,” he said. “Technology is changing. We’re now getting real data. We know what the outcomes are in hospitals. We’re all humans, we’re all a little bit competitive, and I think you react to data. This will make a difference.”
In a keynote address, Don Berwick, MD, MPP, FRCP, former administrator of the Centers for Medicare and Medicaid Services, pointed out that one in four hospital patients experience injury as a result of their care.
“Healthcare is far too unsafe,” said Berwick. “A large proportion of patient safety problems can be eliminated. There are hospitals in this nation that have driven certain kinds of infections to zero and virtually eliminated the risk of pneumonia from ventilation machines.”
Berwick suggested that healthcare systems can learn from many of the safety practices that the aviation industry has successfully put in place. “Today, you would have to fly continuously on a commercial flight for over 6,000 years to have a 50:50 chance of being injured as a passenger,” he said. “Roughly speaking, that means you are more than two million times safer in an airplane seat than in a hospital.”
Jannicke Mellin-Olsen, former president of the World Federation of Societies of Anesthesiologists, used her keynote address to call for more healthcare systems to involve patients and family members of those who have suffered harm in order to help drive better practices. “Involvement means hearing the patient voice at every level of the service,” she said.
The first day of the Summit also featured a talk from Sir Liam Donaldson, former chief medical officer of the United Kingdom, who discussed the impact of Covid-19 on patient safety and how the pandemic illustrated the lack of resilience throughout our healthcare structures. “There wasn’t much thinking about patient safety in the pandemic planning that preceded Covid,” said Donaldson. “Failures to develop world-class infection control facilities put both health workers and patients at risk, but there was also the issue of transitions of care, which greatly affected elderly patients and led to the virus spreading through nursing homes. That should have been part of our thinking from a patient safety perspective.”
Neelam Dhingra, who heads the World Health Organization’s (WHO) Transformative Flagship Initiative, emphasized the need to improve patient safety in low- and middle-income countries. Dhingra pointed out how when WHO conducted a survey of 102 countries in 2022, just 27% had developed a national patient safety action plan, and only 18% had established national targets on reducing medication-related harm.
“In low- and middle-income countries, we are still very far from even simple procedures when it comes to patient safety,” said Dhingra. “Studies from these countries are limited, but the estimates we have suggest that every minute at least five patients die in hospital. This means that the burden of harm in healthcare is grossly underestimated.”
Konrad Reinhart, founding president of the Global Sepsis Alliance, highlighted the continuing need to improve public awareness on sepsis and push for hospitals to comply with best practices. “Given the number of sepsis deaths worldwide, which are higher than cancer, the potential to reduce harm is enormous,” he said.
There were additional talks from world-renowned patient safety champion Peter Pronovost, along with Stephanie Mercado, chief executive officer of the National Association for Healthcare Quality, and Peter Lachman who leads the PSMF’s Fellowship Program. Tedros Adhanom Ghebreyesus, director general of WHO, addressed the Summit in a prerecorded video message.
Panel discussions included contributions from members of the President’s Council of Advisors on Science and Technology regarding their upcoming report on patient safety, as well as an assessment from healthcare leaders on the potential of predictive analytics and AI to improve patient safety.
Other panels touched on subjects ranging from the need for patient and family engagement in healthcare to proposals for forming a National Patient Safety Board. The day’s program ended with a private screening of the HBO documentary Bleed Out.
ABOUT THE PATIENT SAFETY MOVEMENT FOUNDATION
In 2012, Joe Kiani founded the non-profit Patient Safety Movement Foundation (PSMF) to eliminate preventable medical errors in hospitals. His team worked with patient safety experts from around the world to create Actionable Evidence-Based Practices (AEBP) that address the top challenges. The AEBP are available without charge to hospitals online. Hospitals are encouraged to make a formal commitment to ZERO preventable deaths, and healthcare technology companies are asked to sign the Open Data Pledge to share their data so that predictive algorithms that can identify errors before they become fatal can be developed. The Foundation's annual World Patient Safety, Science & Technology Summit brings together all stakeholders, including patients, healthcare providers, medical technology companies, government employers, and private payers. The PSMF was established through the support of the Masimo Foundation for Ethics, Innovation, and Competition in Healthcare. For more information, please visit psmf.org.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230601006140/en/
Contact information
Patient Safety Movement Foundation
Irene Mulonni, irene@mulonni.com | (858) 859-7001
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
VerSprite Launches Fork and Knife: AI-Driven Threat Modeling and Adversarial Testing Built for the Speed of Modern Software27.6.2026 00:28:00 EEST | Press release
VerSprite, a global leader in risk-based threat modeling and the firm behind the PASTA (Process for Attack Simulation and Threat Analysis) methodology, today announced the general availability of Fork (www.forktm.com), a continuous application threat modeling platform, alongside Knife, an AI-led, human-on-the-loop adversarial testing platform for web applications and web API endpoints. Together, the two products operationalize a new model for product security—one where applications are securely designed, continuously modeled, and actively tested as part of the build process itself. The launch addresses a problem every security leader knows but few tools have solved: threat modeling is essential, never more so than in an AI-driven era, yet it has remained slow, manual, and anchored to frameworks designed for a different threat landscape. The problem: threat modeling matters more than ever—and most tools are stuck in 2005 For two decades, application threat modeling has leaned heavily on
Venture Global Announces Closing of $1.5 Billion Senior Secured Vessel Financing Facility26.6.2026 23:30:00 EEST | Press release
Venture Global, Inc. (NYSE: VG) announced today that its wholly-owned subsidiary, Venture Global Shipping Holdings, LLC (“VGSH”), has entered into a Credit and Guaranty Agreement providing for a senior secured term loan facility (the “Facility”) in an aggregate principal amount of up to $1,500,000,000. The Facility will mature on June 26, 2032. Deutsche Bank and ING acted as coordinating lead arrangers for the Facility. ING also serves as facility agent and security trustee. VGSH intends to use the net proceeds from the Facility for general corporate purposes, including to reimburse Venture Global LNG, Inc. for payments previously made by it or its affiliates in connection with the acquisition of nine LNG carriers, funding certain reserve accounts, and paying transaction fees and expenses. About Venture Global Venture Global is an American producer and exporter of low-cost U.S. liquefied natural gas (“LNG”) with over 100 MTPA of capacity in production, construction, or development. Ven
Capco Recognized by OpenAI for Innovation and Responsible AI Leadership26.6.2026 21:00:00 EEST | Press release
Global management and technology consultancy Capco, a Wipro company,has been recognized by OpenAI for both AI innovation and responsible AI leadership. Capco received the AI Governance & Risk Excellence Award at the recent OpenAI Partner Summit 2026 in San Francisco, highlighting Capco’s ability to deliver enterprise-grade AI outcomes in highly regulated environments. The award recognizes Capco’s expert advantage when helping financial services and energy organizations to scale AI with confidence, balancing innovation with strong governance to reduce risk, strengthen compliance and improve customer outcomes. This award follows Capco winning the OpenAI Codex Hackathon, where its UK AI Lab competed against more than 30 teams and over 100 participants from across the OpenAI partner ecosystem. Capco's winning entry Sentra – a consulting-led, AI-powered retail banking solution – uses digital twin technology to identify vulnerable customers and recommend explainable next-best actions for fro
Incyte Announces Positive CHMP Opinion for Opzelura ® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 14:30:00 EEST | Press release
Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs) are inadequate or inappropriate. “AD is a chronic skin condition that can have a significant impact on daily life. The positive CHMP opinion for Opzelura marks meaningful progress toward bringing the first non-steroidal topical JAK treatment option to adults in Europe with moderate AD for whom standard topical therapies have failed,” said Lee Heeson, Executive Vice President and Head of Incyte International. “If approved by the European Commission, Opzelura could help address an important gap for patients who have limited treatment options when TCSs and TCIs are inadequate or inappropriate.” The positive CHMP o
Datroway ® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 14:00:00 EEST | Press release
Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the TROPION-Breast02phase 3 trial, which werepresented at the 2025 European Society for Medical Oncology Congress and published in Annals of Oncology. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In TROPION-Breast02, Datroway demonstrated a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
